{
    "clinical_study": {
        "@rank": "130952", 
        "arm_group": [
            {
                "arm_group_label": "Risperidone, Comparator, Subcu injection", 
                "arm_group_type": "Active Comparator", 
                "description": "Risperidone 2mg oral and RBP-7000 60mg injection"
            }, 
            {
                "arm_group_label": "Risperidone, Comparator, Subcutaneous", 
                "arm_group_type": "Active Comparator", 
                "description": "Risperidone 3mg oral and RBP-7000 90mg injection"
            }, 
            {
                "arm_group_label": "Risperidone, comparator, injection", 
                "arm_group_type": "Active Comparator", 
                "description": "Risperidone 4mg oral and RBP-7000 120mg injection"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages\n      of risperidone with clinically stable schizophrenia"
        }, 
        "brief_title": "Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "This will be an open-label, Phase 2A, multiple ascending dose study in 1 to 3 sites,\n      designed to evaluate the safety, tolerability, and PK profile of multiple subcutaneous\n      injections of 60mg, 90mg, and 120mg doses of risperidone in the RBP-7000 formulation, in\n      subjects with clinically-stable schizophrenia who are on a once daily stable dose of 2mg,\n      3mg, or 4mg of oral risperidone"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female\n\n          -  > 18 to < 65 years\n\n          -  Diagnosis of paranoid, residual, or undifferentiated schizophrenia as   defined by\n             DSM-IV-TR criteria\n\n               -  Status: clinically stable subjects defined as subjects with no hospitalizations\n                  for acute exacerbations within 3 months of screening and screening total PANSS\n                  score < 60\n\n          -  Subjects who have given written informed consent\n\n        Exclusion Criteria:\n\n          -  Subjects taking any risperidone sustained release formulation within the 60 days\n             prior to study screening\n\n          -  Subjects taking the following concurrent medication/over-the-counter products:\n\n          -  Inducers or inhibitors of CYP2DD6 within 14 days or 7 half - lives (whichever occurs\n             last) prior to study screening\n\n          -  Bupropion, chlorpheniramine, cimetidine, clomipramine, doxepin, or quinidine within\n             30 days prior to study screening\n\n          -  Clozapine, phenothiazines, aripiprazole, haloperidol, or any other antipsychotic\n             other than oral risperidone within 14 days prior to study screening\n\n          -  Selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine) or\n             serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine, desvenlafaxine,\n             duloxetine) within 30 days prior to study screening\n\n          -  Opioids or opioid-containing analgesics within 14 days prior to study screening\n\n          -  Medications, in addition to those listed above, which may be expected to\n             significantly interfere with the metabolism or excretion of risperidone and/or\n             9-hydroxyrisperidone, that may be associated with a significant drug interaction with\n             risperidone, or that may pose a significant risk to subjects' participation in the\n             study\n\n          -  Subjects with a history of cancer (with the exception of resected basal cell or\n             squamous cell carcinoma of the skin) unless they have been disease free for >5 years\n\n          -  Subjects with another active medical condition or organ disease that may either\n             compromise subject safety and/or outcome evaluation of the study drug\n\n          -  Subjects with evidence or history of a significant hepatic disorder that may either\n             compromise subject safety or interfere with the safety and/or outcome evaluation of\n             the study drug.  Individuals with acute hepatitis (including but not limited to B or\n             C); or individuals with 1) total bilirubin >1.5x the upper limit oof normal and/or 2)\n             alanine aminotransferase or aspartate aminotransferase >2x upper limit of normal will\n             be excluded\n\n          -  Subjects with hepatitis C antibody and AST, ALT, or alkaline phosphatase >2x and\n             total bilirubin >1.3 mg/dL will be excluded\n\n          -  Subjects with a history of renal disease, or a creatinine clearance of less than 80\n             mL/min (as determined by the Cockcroft Gault formula)\n\n          -  Subjects with an international normalized ratio >2.0 at screening\n\n          -  Subjects with corrected QT interval (Bazett's - QTcB) >450 msec (male) or >470 msec\n             (female) at screening.  Subjects with a QTc above these levels due to a benign right\n             bundle branch block can be included in the study at the discretion of the PI\n\n          -  Subjects who are known to have AIDS or to be HIV positive\n\n          -  Subjects with suicidal ideation with intent and plan (C-SSRS affirmative answers to\n             questions 4 and 5 of the ideation section) or suicide attempts within the last six\n             months as noted on the C-SSRS, or subjects with uncontrolled depression in the\n             opinion of the investigator\n\n          -  Subjects with known diagnosis of type 1 or 2 diabetes or subjects with Hemoglobin A1c\n             >7.0 at screening\n\n          -  Subjects who have participated in a clinical trial within 30 days prior to study\n             screening\n\n          -  Subjects who meet the DSM-IV-TR criteria for alcohol abuse or dependence within the\n             last six months of screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677377", 
            "org_study_id": "RB-US-09-0009"
        }, 
        "intervention": {
            "arm_group_label": [
                "Risperidone, Comparator, Subcu injection", 
                "Risperidone, Comparator, Subcutaneous", 
                "Risperidone, comparator, injection"
            ], 
            "description": "2mg, 3mg, and 4mg oral and 60mg, 90mg, and 120mg subcutaneous injection", 
            "intervention_name": "Risperidone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Risperidone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Schizophrenia", 
            "Schizophrenic", 
            "Schizophrenias"
        ], 
        "lastchanged_date": "September 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Alaska", 
                        "zip": "72211"
                    }, 
                    "name": "Woodland International Research Group, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Ocean View Psychiatric Health Facility"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 2A Study as an Open Label, Multiple Ascending Dose With Randomized Subjects to Receive a Single Dose of One of Three Dose Levels", 
        "overall_official": [
            {
                "affiliation": "Pharmaceutical Research Associates, Inc.", 
                "last_name": "Philippa Whitelaw, Sr. Dir of Proj Deliver", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Pharmaceutical Research Associates, Inc.", 
                "last_name": "Ashley Huston, PMP", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety variables to be analyzed are: adverse events, local injection site tolerability, concomitant medications, changes in clinical laboratory results, vital sign measurements, 12-lead electrocardiograms, physical examination results, body weights, and monitoring of extrapyramidal symptoms using neurological and clinical symptom assessments", 
                "measure": "To assess the safety and tolerability of multiple subcutaneous injections of RBP-7000", 
                "safety_issue": "Yes", 
                "time_frame": "Day -14, Day 1, up to Day 106"
            }, 
            {
                "description": "To evaluate the pharmacokinetic profiles of risperidone, 9-hydroxyrisperidone, and total active moiety after multiple subcutaneous injections", 
                "measure": "To evaluate the pharmacokinetic (PK) profiles of risperidone", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1, Day 87, up to Day 106"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677377"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the switch from oral risperidone to RBP-7000 subcutaneous injections for efficacy markers using the positive and negative Syndrome Scale and Clinical Global Impression Scale for Schizophrenia as the primary markers of efficacy", 
                "measure": "To evaluate switch from oral to subcutaneous injection of risperidone", 
                "safety_issue": "Yes", 
                "time_frame": "Day -14, Day 1, up to Day 106"
            }, 
            {
                "description": "To evaluate the switch from oral risperidone to RBP-7000 subcutaneous injections for efficacy markers using the Abnormal Involuntary Movement Scale for Tardive Dyskinesia, Simpson-Angus Scale, Barnes Akathisia Scale, and Columbia-Suicide Severity Rating Scale", 
                "measure": "To evaluate switch from oral to subcutaneous injection of risperidone", 
                "safety_issue": "Yes", 
                "time_frame": "Day -14, Day 1, up to Day 106"
            }
        ], 
        "source": "Reckitt Benckiser Pharmaceuticals Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reckitt Benckiser Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }
}